六价疫苗与甲乙肝联合疫苗在造血干细胞移植受者中的乙肝免疫原性比较
该回顾性队列研究纳入2017至2023年巴塞罗那某三级医院的331例成人造血干细胞移植受者,比较六价疫苗与甲乙肝联合疫苗的乙肝免疫原性。结果显示六价疫苗组血清保护率显著更高(70.1% vs 42.3%,p<0.001),多因素分析中六价疫苗接种与移植前血清保护均与更高应答相关。
要点
- 六价疫苗组血清保护率70.1%,显著高于甲乙肝联合疫苗组的42.3%。
- 六价疫苗接种(OR 4.27)和移植前血清保护(OR 9.36)与更高应答独立相关。
- 他克莫司使用和多发性骨髓瘤与较低免疫应答相关。
核心结论
- 尽管六价疫苗乙肝抗原含量较低,但其在成人造血干细胞移植受者中与显著更高的血清保护率相关。
研究设计与样本
- 回顾性队列研究,纳入2017至2023年巴塞罗那某三级医院331例成人造血干细胞移植受者,中位年龄54.6岁,女性占42.3%。
- 患者于2017-2019年接种甲乙肝联合疫苗,或于2020-2023年接种六价疫苗。
- 血清保护定义为第三剂后一个月HBsAb ≥10 IU/mL,采用单因素和多因素logistic回归分析相关因素。
主要发现
- 六价疫苗组血清保护率为70.1%,甲乙肝联合疫苗组为42.3%(p < 0.001)。
- 六价疫苗组HBsAb中位滴度为668 IU/mL,联合疫苗组为375 IU/mL(p = 0.261),差异无统计学意义。
- 多因素分析显示,六价疫苗接种(OR 4.27,95% CI 2.88-6.36)和移植前血清保护(OR 9.36,95% CI 5.46-16.03)与更高应答相关。
- 他克莫司使用和多发性骨髓瘤与较低应答相关。
关键数值与推荐
- 血清保护标准:第三剂乙肝疫苗后一个月HBsAb ≥10 IU/mL。
- 六价疫苗组血清保护率70.1%,甲乙肝联合疫苗组42.3%(p < 0.001)。
临床怎么用
- 对于成人造血干细胞移植受者,可优先考虑使用六价疫苗接种以提升乙肝血清保护率。
- 移植前已存在保护性HBsAb滴度者应答更佳,提示应关注移植前免疫状态。
- 使用他克莫司或多发性骨髓瘤患者接种后应答可能降低,需加强监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In 2020, the Catalan Department of Health recommended a pediatric hexavalent vaccine for adult hematopoietic stem cell transplant (HSCT) recipients. Previously, patients at our center received a combined hepatitis A + B vaccine with double the hepatitis B antigen content. The immunogenicity of the hexavalent formulation in this population remains unclear. OBJECTIVE: To compare immunogenicity of two hepatitis B vaccination strategies in adult HSCT recipients and identify predictors of response. METHODS: We conducted a retrospective cohort study including adult HSCT recipients vaccinated between 2017 and 2023 in a tertiary hospital in Barcelona. Patients received hepatitis A + B vaccine (2017-2019) or hexavalent vaccine (2020-2023). Seroprotection was defined as HBsAb ≥10 IU/mL one month after the third dose. Univariate and multivariate logistic regression were used to identify factors associated with seroresponse. RESULTS: A total of 331 patients were included (median age 54.6 years; 42.3% female). Seroprotection rates were higher with the hexavalent vaccine compared to hepatitis A + B (70.1% vs. 42.3%; p < 0.001). Median HBsAb titers were higher but not statistically significant (668 vs. 375 IU/mL; p = 0.261) in the hexavalent group. In multivariate analysis, hexavalent vaccination (OR 4.27, 95% CI 2.88-6.36) and pre-HSCT seroprotection (OR 9.36, 95% CI 5.46-16.03) were associated with higher response. Tacrolimus use and multiple myeloma were associated with lower response. CONCLUSIONS: Despite lower antigen content, the hexavalent vaccine was associated with significantly higher seroprotection in adult HSCT recipients. Pre-existing protective HBsAb titers enhanced response, whereas tacrolimus exposure and multiple myeloma were associated with reduced immunogenicity.
引用
- Montes Camiño LM, Aldea M, Martínez C, et al. Evaluation of the immunogenicity of hepatitis B vaccination in hematopoietic stem cell transplant recipients vaccinated with a hexavalent vaccine compared with patients vaccinated with a combined hepatitis A and B vaccine. Vaccine. 2026. PMID: 42801864. doi:10.1016/j.vaccine.2026.129183
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。